Cytokinetics’ Q1 results were buoyed by the strong commercial launch of MYQORZO in the U.S., with initial revenue and prescriber engagement exceeding internal expectations, driving a 13.3% stock gain.

• MYQORZO generated $4.8 million in net product revenue in its first partial commercial quarter.
• Over 90% of high-volume cardiomyopathy (CMI) prescribing physicians were detailed by the sales force in Q1.
• More than 40% of MYQORZO prescriptions came from lower-volume or first-time CMI prescribers, indicating early breadth in adoption.
• Positive topline Phase III results from ACACIA-HCM showed aficamten improved symptoms and exercise capacity in nonobstructive HCM with no new safety concerns.
• Regulatory progress includes FDA acceptance of the MAPLE-HCM supplemental NDA with a PDUFA date set for November 14, 2026, and filings or approvals advancing in Europe, Switzerland, Canada, Hong Kong, and Taiwan.